CurrentBlue Cross Blue Shield - MassachusettsPolicy 329

Fecal Calprotectin Testing Policy

Defines medical necessity, investigational status, prior authorization requirements, and applicable CPT/ICD-10 coding for fecal calprotectin (CPT 83993) for commercial and Medicare members of Blue Cross Blue Shield Massachusetts.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyFecal Calprotectin Testing Policy

Policy CodePolicy 329

Change TypeRevised (3/2024)Clarified coding (10/2025)Annual review (2/2026)

Effective DateMar 1, 2024

Next Review Date

Key ActionProviders should submit one of the listed ICD-10-CM diagnosis codes with CPT 83993 and ensure medical necessity criteria are met.

SourceLink

POLICY UPDATE CHANGES

10/2025: Clarified coding information.

3/2024: Policy revised to include medically necessary indications for fecal calprotectin testing in the management of bowel disease, active IBD and surveillance for relapse of disease in remission.

2/2026: Annual policy review updated with literature through November 4, 2025; references added. Policy statements unchanged.

1Covered CPT codes

~60+Listed ICD-10 codes

3Not covered / investigational uses listed

Inpatient PAAuthorization requirement

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

Overview: This policy (Policy Number 329) addresses Fecal Calprotectin Testing and defines medical necessity, investigational status, prior authorization requirements, and applicable CPT/ICD-10 coding for fecal calprotectin (CPT 83993). Effective date: 2024-03-01. Coverage stance: mixed. Status: CURRENT.

Surface thresholds and quick reference facts

Common laboratory cutoff50 µg/g (recommended lower bound for adults and children >4 years)

Age-related noteModerate increases up to 100 µg/g described for individuals >65 years; physiologically higher in neonates/infants/young children

Dates - effective2024-03-01

Dates - last review2026-02-01

Scope summaryDefines medical necessity, investigational status, prior authorization requirements, and applicable CPT/ICD-10 coding for fecal calprotectin (CPT 83993) for commercial and Medicare members of Blue Cross Blue Shield Massachusetts.

Medical-Necessity Criteria

Medically Necessary (Commercial and Medicare Members)

Fecal calprotectin testing is considered MEDICALLY NECESSARY when ALL of the following clinical criteria are met:

ALL of the following

Differential diagnosis includes inflammatory bowel disease (IBD) versus noninflammatory bowel disease (including irritable bowel syndrome) and endoscopy with biopsy is being considered

Medically Necessary for Management of Bowel Disease

Fecal calprotectin testing is considered MEDICALLY NECESSARY in the management of bowel disease when ANY of the following apply:

ANY of the following

Monitoring active inflammatory bowel disease

Coding

Covered CPTCPTCovered

83993

Calprotectin; fecal

Applicable ICD-10-CM Diagnosis Codes (medically necessary when submitted with CPT 83993 and criteria met)ICD-10Covered

K50.00	Crohn's disease of small intestine without complications
K50.011	Crohn's disease of small intestine with rectal bleeding
K50.012	Crohn's disease of small intestine with intestinal obstruction
K50.013	Crohn's disease of small intestine with fistula
K50.014	Crohn's disease of small intestine with abscess
K50.018	Crohn's disease of small intestine with other complication
K50.019	Crohn's disease of small intestine with unspecified complications
K50.10	Crohn's disease of large intestine without complications
K50.111	Crohn's disease of large intestine with rectal bleeding
K50.112	Crohn's disease of large intestine with intestinal obstruction

1–10 of 97

1/10

Provider Actions & Billing Requirements

Prior Authorization

Inpatient prior authorization required

Precertification/preauthorization IS REQUIRED for services described in this policy if performed inpatient for all products.

Precertification/preauthorization IS REQUIRED if performed inpatient for all products.

Documentation Required

Submit appropriate ICD-10 with CPT 83993

Providers should submit one of the listed ICD-10-CM diagnosis codes with CPT 83993 and ensure medical necessity criteria are met.

83993
Submit one of the listed ICD-10-CM diagnosis codes with CPT 83993 and ensure medical necessity criteria are met.

Background, Evidence, and Definitions

Background: Fecal calprotectin is a stable fecal protein marker of neutrophilic intestinal inflammation used to distinguish IBD from non-IBD, to help select patients for endoscopy, to monitor disease activity, and to predict relapse. A commonly used cutoff is 50 µg/g (recommended lower bound for adults and children >4 years), but values vary by age (higher in neonates/infants/young children and moderately increased up to 100 µg/g in individuals >65 years) and may be elevated by medications (eg, NSAIDs, proton pump inhibitors) and other clinical situations (eg, GI bleeding).

Evidence Item	Summary
Diagnostic sensitivity at 50 µg/g
Reported sensitivity 93% to 99% in select studies; negative predictive value 73% to 100%; most studies used 50 µg/g cutoff to indicate disease and this is the recommended lower bound
Predicting relapse (meta-analysis)
Mao et al. (2012) pooled sensitivity 78% and specificity 73% for predicting relapse of quiescent IBD
Impact on colonoscopy use
Incorporating fecal calprotectin into diagnostic work-up may reduce need for colonoscopy by approximately 66.7% in some analyses

Glossary: Fecal calprotectin — a calcium- and zinc-binding protein released from neutrophils; used as a noninvasive marker of intestinal inflammation. (Stable in feces at room temperature for up to one week; typical diagnostic cutoff ~50 µg/g for adults and children >4 years.)

Not Covered / Experimental Uses

Coverage summary (mixed): Fecal calprotectin testing is covered for specific, medically necessary indications but not supported for other uses. Not covered / investigational uses include: Home-based fecal calprotectin testing; Fecal calprotectin testing for any indication not specified as medically necessary (considered investigational); and Fecal calprotectin testing concurrent with lactoferrin testing (considered not medically necessary).

Revision History

2024-03-01revised

Policy revised to include medically necessary indications for fecal calprotectin testing in the management of bowel disease, active inflammatory bowel disease and surveillance for relapse of disease in remission. Effective 3/1/2024.

2025-10-01clarified

Clarified coding information.

2026-02-01annual_reviewLatest